The EU Expands Its "Well-Established Technologies" List Again

The European Commission is continuing to widen the list of medical device technologies eligible for reduced clinical and conformity assessment requirements under the MDR, and manufacturers with devices in dental, orthopedic, cardiovascular, or surgical categories should check whether they now qualify.

What changed

On March 20, 2026, the Commission adopted two delegated regulations amending the MDR's treatment of "well-established technologies" (WET), devices with common, simple, stable designs and long-established safety and performance profiles:

• C(2026) 1798 expands the list of implantable and Class III devices exempt from the obligation to perform a clinical investigation under Article 61(6)(b).
• C(2026) 1809 expands the list of Class IIb implantable devices exempt from per-device technical documentation assessment under Article 52(4), allowing notified bodies to sample rather than review every technical file.

Together, the two regulations pushed the WET list from roughly a dozen device types to approximately 67, adding categories such as sutures, staples, dental fillings, braces and crowns, screws, wedges, catheters, feeding tubes, bone wax, bone fillers, bone substitutes, dental implants, spinal fixation devices, and cannulas. A further delegated regulation extending the Class IIb list, Delegated Regulation (EU) 2026/1359, published June 29, 2026, entering into force 20 days later, continues that expansion.

What it does not change

Exemption from a clinical investigation is not exemption from clinical evidence. Manufacturers of listed devices still must plan, conduct, and document a full clinical evaluation under Article 61, relying on existing clinical data rather than generating new investigational data. Implant card obligations under Article 18 are also unaffected. A newly listed implantable WET device still requires one.

Why this is worth tracking closely, not just once

Notice how this expansion arrived: not as a single MDR revision, but as a sequence of delegated acts landing across March and June 2026, with Article 52(5) giving the Commission standing authority to expand the list further at any time. A manufacturer who checked the WET list once, in early 2026, and built a clinical strategy around it, is already working from a list roughly five times shorter than the current one. That gap only grows as the Commission continues to use its delegated authority.

Checking a device's WET eligibility once is a compliance snapshot. Checking it continuously, as the Commission keeps adding categories, is what actually lets a manufacturer capture the reduced clinical burden before a competitor does.

Confirm whether any of your Class IIb, Class III, or implantable devices now fall under the expanded lists, and revisit your clinical evaluation plan accordingly rather than assuming your last classification review still holds.

For the regulatory source material, see the European Commission's own notice on the delegated acts, RAPS' coverage of the expanded WET list, and GMED's summary of the June 2026 extension.

For related grounding on MDR conformity routes, see Qualio's what you should know about the CE mark. If your team is tracking MDR updates like this one manually, see how continuous gap analysis surfaces regulatory changes like the WET list as they land.